Last reviewed · How we verify
''albendazole'' and ''ivermectin''
Albendazole and ivermectin are antiparasitic agents that disrupt parasite neuromuscular function, causing paralysis and death of helminths and arthropods.
Albendazole and ivermectin are antiparasitic agents that disrupt parasite neuromuscular function, causing paralysis and death of helminths and arthropods. Used for Soil-transmitted helminthiasis (roundworm, hookworm, whipworm), Lymphatic filariasis, Onchocerciasis (river blindness).
At a glance
| Generic name | ''albendazole'' and ''ivermectin'' |
|---|---|
| Also known as | Zentel and Mectizan |
| Sponsor | Centre d'Appui à la lutte contre la Maladie |
| Drug class | Antihelmintic/Antiparasitic agents |
| Target | β-tubulin (albendazole); glutamate-gated chloride channels (ivermectin) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | FDA-approved |
Mechanism of action
Albendazole inhibits microtubule polymerization in parasitic worms by binding to β-tubulin, disrupting glucose uptake and energy metabolism. Ivermectin binds to glutamate-gated chloride channels in parasites, causing hyperpolarization, paralysis, and expulsion. Together, this combination targets multiple parasite species through complementary mechanisms.
Approved indications
- Soil-transmitted helminthiasis (roundworm, hookworm, whipworm)
- Lymphatic filariasis
- Onchocerciasis (river blindness)
- Schistosomiasis
- Strongyloidiasis
Common side effects
- Gastrointestinal disturbances (nausea, abdominal pain, diarrhea)
- Headache
- Dizziness
- Pruritus (itching)
- Fever
- Elevated liver enzymes
Key clinical trials
- Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole (PHASE3)
- Moxidectin for LF, Cote d'Ivoire (DOLF) (PHASE3)
- Tuberculosis - Learning the Impact of Nutrition (NA)
- Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis (PHASE2)
- Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms (PHASE2, PHASE3)
- Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC (PHASE2)
- Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness (PHASE3)
- Better Options for Lymphatic Filariasis Treatment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: